摘要
目的 :探讨重组组织型纤溶酶原激活剂 (rt PA)静脉溶栓治疗急性心肌梗死 (AMI)的疗效及安全性。方法 :选择 2 0例AMI患者应用rt PA静脉溶栓治疗 ,观察临床症状、心电图、心肌酶谱的变化 ,判断冠状动脉再通率。结果 :① 2 0例AMI患者 ,冠状动脉再通 12例 ,再通率 6 0 %,其中发病 6h以内溶栓再通率 87.5 %(7/ 8) ,发病 6～ 2 4h溶栓再通率 4 1.7%(5 / 12 ) ,两者相比差异有显著性意义 (P <0 .0 5 )。②≤ 6 5岁患者的血管再通率与不良反应发生率与 >6 5岁组相比差异无显著性意义 (P >0 .0 5 )。结论 :rt PA静脉溶栓治疗AMI是一种安全、有效的方法 ,宜提倡急诊室溶栓。 >6 5岁患者行静脉溶栓治疗是安全可行的 ,但要根据患者的具体情况而定。
Objective:To observe the therapeutic effect and safety of brief-duration intravenous infusion of rt-PA in patients with acute myocardial infarction (AMI).Method:Twenty patients with AMI were treated by brief-duration intravenous infusion of rt-PA, the reperfusion rate was evaluated by improvements of clinical symptoms, ECG and myocardium enzyme.Result:① Of the 20 patients, the reperfusion rate was 60%. The reperfusion rate of the patients who received thrombolysis less than 6 hours after the onset of symptoms was much higher than that of between 6～24 hours [ 87.5% (7/8) vs 41.7% (5/12), P< 0.05]. ② There were also no significant differences of side effect between≤65 years group and >65 years group (P> 0.05). The rate of reperfusion arrhythmia was 60%.Conclusion:Brief-duration intravenous infusion of rt-PA in patients with AMI is safe and effective and can be used in the emergency room. It is safe to administer intravenous infusion of rt-PA to patients who are over 65 years old, but their general conditions should be considered carefully.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2002年第3期115-116,共2页
Journal of Clinical Cardiology
